Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Withdrawing off-label antipsychotics in people with intellectual disabilities
2016-002859-19Phase 3Active
- Sponsor
- Erasmus MC
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risperidone and pipamperone in intellectual disability (ID), behavioral disorder and mental disorder (2 arms), sponsored by Erasmus MC. Primary endpoints: Interpretation of behavior, Challenging behavior and 4 more. Started Sep 2016; status: active.
02
Drugs
risperidonepipamperone
03
Conditions
intellectual disability (ID)behavioral disordermental disorder
Beyond the preview
Go deeper on 2016-002859-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002859-19.